Subsequent drug-target MR and SMR analyses, based on eQTL data for seven of these genes, confirmed five genes—FAM120A, GBE1, MCM6, MSRA, and ZDHHC4—as significantly associated with CRC, supporting their potential as therapeutic targets and underscoring the robustness of our gene selection strategy. The gene discussed is ZDHHC4; the disease is colorectal carcinoma.